Stablix

About:

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS).

Website: https://www.stablix.com/

Twitter/X: StablixInc

Top Investors: Alexandria Real Estate Equities, New Enterprise Associates, Cormorant Asset Management, Euclidean Capital, Versant Ventures

Description:

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.

Total Funding Amount:

$63M

Headquarters Location:

New York, New York, United States

Founded Date:

2021-01-01

Contact Email:

info(AT)stablix.com

Founders:

Brian Bowman, Carlo Rizzuto, Henry Colecraft, Kevin Sprott, Scott Kanner

Number of Employees:

11-50

Last Funding Date:

2021-06-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai